A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Trial Details

NCT ID
NCT06375733
Phase
PHASE1 / PHASE2
Sponsor
Genfleet Therapeutics (Shanghai) Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • GFH009
  • Zanubrutinib
Locations (sample)
  • Nanning, China|22.81667,108.31667
  • Zhengzhou, China|34.75778,113.64861

Key Eligibility Criteria

  • Age ≥ 18 years old.
  • Relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including: DLBCL, not specified (NOS), T-cell/histiocyte-rich large B-cell lymphoma (…
  • Relapse or refractory after receiving 2\~4 systemic treatment regimens, at least one of which contains anthracyclines and Rituximab.
  • Must have a measurable lesion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →